Showing 2471-2480 of 5644 results for "".
- PYC’s Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Modelshttps://modernod.com/news/pycs-lead-investigational-drug-vp-001-demonstrates-another-key-functional-improvement-in-patient-derived-models/2478930/PYC Therapeutics announced that the company’s lead investigational drug, VP-001, for the treatment of RP11 has restored function of the retinal pigment epithelium (RPE), the target cells for the therapy, in patient-derived models of the disease. “This result builds further conviction in VP
- Retinal Therapeutics Development Company Oxular Completes $37 Million (£27 million) Financinghttps://modernod.com/news/retinal-therapeutics-development-company-oxular-completes-37-million-27-million-financing/2478922/Oxular announced that it has completed a $37 million (£27 million) to fund planned further clinical development of its lead asset, OXU-001, for the treatment of diabetic macular edema (DME), as well as accelerating development of its early-product pipeline. The financing was led by Forbion
- FCI Ophthalmics Announces Availability of LacriJet for Monocanalicular Nasolacrimal Intubationhttps://modernod.com/news/fci-ophthalmics-announces-availability-of-lacrijet-for-monocanalicular-nasolacrimal-intubation/2478907/FCI Ophthalmics announced the launch of the LacriJet in the United States. It is the first, self-retaining monocanalicular nasolacrimal intubation preloaded on a single use injector, according to FCI Ophthalmics. LacriJet consists of a single use injector handpiece into which a silicone tu
- Asclepix Therapeutics Partners With Notal Vision on Home OCT Remote Monitoring in DME and AMD Clinical Trialshttps://modernod.com/news/asclepix-therapeutics-partners-with-notal-vision-on-home-oct-remote-monitoring-in-dme-and-amd-clinical-trials/2478900/Notal Vision announced that the company will provide AsclepiX Therapeutics with Home OCT monitoring services through its Notal Vision Diagnostic Clinic to support AsclepiX’s AXT107 phase 1 clinical trial program. The
- Nicox Announces the Publication of Preclinical Efficacy Results on a New Class of Non-PGA NO-Donating IOP-Lowering Compoundshttps://modernod.com/news/nicox-announces-the-publication-of-preclinical-efficacy-results-on-a-new-class-of-non-pga-no-donating-iop-lowering-compounds/2478896/Nicox SA announced the publication of preclinical IOP-lowering results on a new class of non-prostaglandin analog (PGA), nitric oxide (NO)-donating compounds, in the Journal of Ocular Pharmacology and Therapeutics.1 The NO-mediated IOP-lowering effect in this new class of comp
- Life Biosciences Announces Research in Nature Describing New Mechanisms for Reversing Age-Related Diseasehttps://modernod.com/news/life-biosciences-announces-research-in-nature-describing-new-mechanisms-for-reversing-age-related-disease/2478889/Life Biosciences has in-licensed intellectual property related to scientific findings recently described in two publications in the journal Nature. The publications, based on research conducted in animal models, report that therapies targeting the biology of aging have the potential to not
- Focus Vitamins Unveils New Blue Light Product to Help Protect Eyes from Digital Devices and Eye Fatiguehttps://modernod.com/news/focus-vitamins-unveils-new-blue-light-product-to-help-protect-eyes-from-digital-devices-and-eye-fatigue/2478855/Covalent Medical, owner of the brand “Focus Vitamins,” announced today that their new Blue Light mango-flavored gummy will be available to their partner physician practices for resale. “The B.L.U.E. study shows using electronic digital devices can cause eye fatigue, and even interrupt slee
- Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of Covaxin in the US Markethttps://modernod.com/news/ocugen-and-bharat-biotech-announce-execution-of-definitive-agreement-for-the-commercialization-of-covaxin-in-the-us-market/2478849/Ocugen and Bharat Biotech announced they have entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech’s Covaxin, an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the United States market. Under th
- Lumibird Medical Creates Three Nordics Subsidiarieshttps://modernod.com/news/lumibird-medical-creates-three-nordics-subsidiaries/2478848/The Lumibird Medical Group announced the creation of Lumibird Medical Nordics AB in Sweden, Lumibird Medical Nordics OY in Finland, and Lumibird Medical Nordics AS in Norway. The creation of these three subsidi
- JCRS Publishes Phase 2 Nepafenac Clinical Trial With Evolute Sustained Drug Delivery Systemhttps://modernod.com/news/jcrs-publishes-phase-2-nepafenac-clinical-trial-with-evolute-sustained-drug-delivery-system/2478843/Mati Therapeutics announced that a peer reviewed manuscript of a phase 2 clinical trial evaluating the safety and efficacy of Nepafenac delivered via Mati’s proprietary Evolute sustained ocular drug delivery platform has been published in the February Journal of Cataract and Refractive Surgery